NICE rejects drug for metastatic breast cancer because of cost and poor efficacy

BMJ 2010; 340 doi: (Published 11 June 2010) Cite this as: BMJ 2010;340:c3145
  1. Mark Pownall
  1. 1London

    The National Institute for Health and Clinical Excellence (NICE) has rejected use of the cancer drug lapatinib in advanced or metastatic breast cancer that is ErbB2/HER 2 positive because of the treatment’s high cost and “small extra benefit” compared with existing treatments.

    Final draft guidance from NICE, which is not yet a formal recommendation to the NHS, says treatment with the drug costs about £25 000 (€30 100; $36 500) per year, and extends survival by about 10 weeks.

    NICE concluded that “the drug did not represent good value for money when compared with the alternative, currently available …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription